Description
Do you have a passion for Regulatory Affairs? Would you like to apply this passion in a growing European Pharmaceutical company where patients truly matters to us? Then this role at Norgine is for you!
In this key role in our business, you will be responsible for preparing high quality documentation for straightforward regulatory submissions; liaising with relevant departments and ensuring that regulatory requirements for these submissions are met. You will communicate with regulatory authorities in order to expedite approval of these submissions with guidance or assistance as required.
Sounds interesting? Then read on…
In this role, you will liaise with relevant internal departments and external contacts to ensure regulatory requirements for all submissions are met and to communicate with regulatory authorities in order to expedite approval of submissions, both independently and as directed by line manage. you will also prepare and maintain, product labelling for appropriate markets in cooperation with local regulatory and commercial contacts, whilst resolving straightforward regulatory issues and to assist in the resolution of more complex issues.
At Norgine, we look for the following skills, exprience and knowledge in our Regulatory Affairs Executive:
If this resonates and is what you might be searching for, apply now!
A recent acquisition by Goldman-Sachs, Norgine is a leading European
specialist pharmaceutical company that has been bringing transformative
medicines to patients for over a century. Our commitment to transforming
people’s lives drives everything we do and our European experience, fully
integrated infrastructure and exceptional partnership approach enables us to quickly
apply creative solutions to bring life-changing medicines to patients that they
may not otherwise be able to access. Norgine is proud to have helped 24 million
patients around the world in and generated € million in net product
sales, a growth of 10% over .
Norgine has a direct presence in 16 European countries, as well as Australia and New
Zealand. We also have a strong global network of partnerships in non-Norgine
markets. We are a flexible and fully integrated pharmaceutical business, with
manufacturing (Hengoed, Wales and Dreux, France), third party supply networks
and significant product development capabilities, in addition to our sales and
marketing infrastructure. This enables us to acquire, develop and commercialise
specialist and innovative products that make a real difference to the lives of
patients around the world. In December , the Private Equity business within
Goldman Sachs Asset Management has completed its acquisition of a majority
stake in the company. With Goldman Sachs Asset Management as its key
partner, Norgine is strongly positioned to deliver on its mission of bringing
transformative medicines to market while purposefully putting patients at the
heart of its strategy.
In , Norgine established Norgine Ventures, a complementary business which
supports innovative healthcare companies through the provision of debt-like
financing in Europe and the US. For more information, please .
NORGINE and the sail logo are trademarks of the Norgine group of companies.